Keros Therapeutics CEO to Present at Healthcare Conferences

By Hao Liu • Friday, August 29 06:05 • Permanent Link

Keros Therapeutics, Inc. has announced its participation in two upcoming healthcare conferences, with the company's President and Chief Executive Officer, Jasbir S. Seehra, Ph.D., set to present at both events. The first conference is the 2025 Wells Fargo Healthcare Conference, scheduled for Thursday, September 4, 2025, at 2:15 p.m. Eastern time. Dr. Seehra's presentation will be in the format of a Fireside Chat.

The second conference is the H.C. Wainwright 27th Annual Global Investment Conference, taking place on Tuesday, September 9, 2025, at 12:00 p.m. Eastern time. The presentation will be in the format of a Corporate Presentation.

For those unable to attend, an archived replay of each presentation will be available in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of each event.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins. The company's lead product candidate, KER-065, is being developed for the treatment of neuromuscular diseases, initially targeting Duchenne muscular dystrophy. Additionally, Keros is developing elritercept for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis. The market has reacted to these announcements by moving the company's shares -1.09% to a price of $15.35. For the full picture, make sure to review Keros Therapeutics's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.